

Latin America Biosimulation Market Report and Forecast 2024-2032

Market Report | 2024-06-26 | 140 pages | EMR Inc.

AVAILABLE LICENSES:

- Single User License \$3999.00
- Five User License \$5299.00
- Corporate License \$6299.00

Report description:

Latin America Biosimulation Market Report and Forecast 2024-2032

Latin America Biosimulation Market Size

The global biosimulation market was valued at USD 3.5 billion in 2023, with Latin America holding a significant market share. The market is driven by the increased focus on pharmaceutical research and development. It is expected to grow at a CAGR of 16.90% during the forecast period of 2024-2032, with the values likely to attain USD 14.1 billion by 2032.

Latin America Biosimulation Market Outlook

- This rising prevalence of chronic diseases is fuelling the adoption of biosimulation tools in the Latin American region, leading to accelerated drug development process and improved patient outcomes, thereby bolstering market growth.
- One of the major Latin America biosimulation market trends is the increased investment in research and development (R&D), particularly in the life sciences domain, which is poised to support the market expansion for biosimulation tools and services.
- According to the International Trade Administration, Brazil has the largest healthcare market in Latin America, spending 9.47% of its GDP on healthcare, which amounts to USD 161 billion. The increased allocation of resources to healthcare is likely to augment the market demand for advanced solutions like biosimulation software.

Latin America Biosimulation Market Analysis

Biosimulation is a robust tool to model and simulate biological processes. Biosimulation models help to mimic the behavior of biological systems and offer insights into their functions, interactions, and responses to various conditions. They can help identify potential drug candidates and predict adverse effects before conducting clinical trials, thus, saving time and money. The growing adoption of biosimulation technologies to accelerate the drug development process and improve patient outcomes is significantly contributing to the Latin America biosimulation market growth.

In Latin America, chronic diseases are a major cause of premature death, decreased quality of life, and substantial economic burden. This rising prevalence of chronic diseases is influencing the adoption of biosimulation tools to develop novel therapeutics for these conditions. Biosimulation techniques not only help in predicting long-term outcomes of therapies but also enhance the

design of clinical trials, thus leading to improved patient outcomes. Further, personalized medicine is gaining traction in the region, driven by the understanding that genetic factors considerably impact drug response. The growing interest in personalized medicine and precision care is likely to augment the Latin America biosimulation market demand.

Latin American countries are gradually increasing their investment in research and development (R&D), particularly in the life sciences domain, which is anticipated to fuel the market share. In December 2023, a study published in the Journal of Law Medicine & Ethics revealed that R&D expenditure is rising in the region, with Brazil spending the largest share of their GDP on healthcare research. Some countries in the Latin American region were reported to make notable progress in pharmaceutical and biotechnology outputs. Thus, the increasing R&D spending is poised to bolster the demand for biosimulation tools and services to support pharmaceutical innovation.

Various factors such as rising healthcare spending, favorable regulatory policies, and the expansion of the pharmaceutical industry are likely to elevate the Latin America biosimulation market value. According to the International Trade Administration, Brazil has the largest healthcare market in Latin America, spending 9.47% of its GDP on healthcare, which amounts to USD 161 billion. With more resources allocated to healthcare, the demand for advanced solutions such as biosimulation software is anticipated to increase in drug discovery and development activities, which will ultimately support the market growth.

Latin America Biosimulation Market Segmentation??

The report offers a detailed analysis of the market based on the following segments:

Market Breakup by Product Type

? Services

?[Software

Market Breakup by Application
?
Drug Development
Drug Discovery
Tother Applications

Market Breakup by Delivery Type ?

Subscription Model

Model

Market Breakup by End User
?[Biotechnology and Pharmaceutical Companies
?[Research Institutes
?[Regulatory Authorities
?[Contract Research Organizations

Market Breakup by Country
?[Brazil
?[Argentina
?[Mexico
?[Others

Leading Players in the Latin America Biosimulation Market

The key features of the market report include patent analysis, grants analysis, funding and investment analysis, partnerships, and collaborations analysis by the leading key players. The major companies in the market are as follows:

- -□In Silico Biosciences
- -□Biosimulation Solutions LLC

Scotts International, EU Vat number: PL 6772247784

- -∏Solvias
- -□QuantumBio
- Biosimulation Technology
- □Biocellion
- -∏Certara
- -∏Simulations Plus
- Rhenovia Pharma
- -∏Heuristik

Kindly note that this only represents a partial list of companies, and the complete list has been provided in the report.

FAOs

- What is the Latin America biosimulation market forecast outlook for 2024-2032?

The Latin America biosimulation market is expected to be driven by the rising demand for the global market, which is anticipated to grow at a CAGR of 16.90% during the forecast period of 2024-2032 and is likely to reach a market value of USD 14.1 billion by 2032.

- What are the major factors aiding the Latin America biosimulation market demand?

The rising advancement in biosimulation software and rising healthcare investments is fuelling the demand for the market.

-\|\What are the major Latin America biosimulation market trends?

One of the significant trends in the market is the rising investment in research and development (R&D) which is poised to bolster the demand for biosimulation tools and services. In December 2023, a Journal of Law Medicine & Ethics study revealed that R&D expenditure is rising in the region, with Brazil spending the largest share of its GDP on healthcare research.

-\|\|What is the market segmentation based on the product type?

Based on the product type, the market is segmented into services and software.

-\|\What is the market breakup by delivery type?

By delivery type, the market is divided into the subscription model and ownership model.

-∏What are the major end users of the market?

End users of the market are biotechnology & pharmaceutical companies, research institutes, regulatory authorities, and contract research organizations.

-∏What are the applications of biosimulation?

Major applications of biosimulation include drug development, and drug discovery, among other applications.

- What is the market segmentation by countries?

The market segmentation by countries includes Brazil, Argentina, and Mexico, among others.

- Who are the key players involved in the Latin America biosimulation market?

The key players in the market are In Silico Biosciences, Biosimulation Solutions LLC, Solvias, QuantumBio, Biosimulation Technology, Biocellion, Certara, Simulations Plus, Rhenovia Pharma, and Heuristik.

Meta description

The Latin America biosimulation market is poised for growth, driven by the expansion of the global market, which was valued at USD 3.5 billion in 2023 and is projected to grow at a CAGR of 16.90% during the forecast period of 2024-2032.

Table of Contents:

1 Preface

Scotts International, EU Vat number: PL 6772247784

tel. 0048 603 394 346 e-mail: support@scotts-international.com

www.scotts-international.com

- 1.1 Objectives of the Study
- 1.2 Key Assumptions
- 1.3 Report Coverage Key Segmentation and Scope
- 1.4 Research Methodology
- 2 Executive Summary
- 3 Latin America Biosimulation Market Overview
 - 3.1 Latin America Biosimulation Market Historical Value (2017-2023)
 - 3.2 Latin America Biosimulation Market Forecast Value (2024-2032)
- 4 Latin America Biosimulation Market Landscape*
 - 4.1 Latin America Biosimulation: Developers Landscape
 - 4.1.1 Analysis by Year of Establishment
 - 4.1.2 Analysis by Company Size
 - 4.1.3 Analysis by Region
 - 4.2 Latin America Biosimulation: Product Landscape
 - 4.2.1 Analysis by Product Type
 - 4.2.2 Analysis by Application
- 5 Latin America Biosimulation Market Dynamics
 - 5.1 Market Drivers and Constraints
 - 5.2 SWOT Analysis
 - 5.2.1 Strengths
 - 5.2.2 Weaknesses
 - 5.2.3 Opportunities
 - 5.2.4 Threats
 - 5.3 Porter's Five Forces Model
 - 5.3.1 Bargaining Power of Suppliers
 - 5.3.2 Bargaining Power of Buyers
 - 5.3.3 Threat of New Entrants
 - 5.3.4 Threat of Substitutes
 - 5.3.5 Degree of Rivalry
 - 5.4 Key Demand Indicators
 - 5.5 Key Price Indicators
 - 5.6 Industry Events, Initiatives, and Trends
 - 5.7 Value Chain Analysis
- 6 Latin America Biosimulation Market Segmentation (2017-2032)
 - 6.1 Latin America Biosimulation Market (2017-2032) by Product Type
 - 6.1.1 Market Overview
 - 6.1.2 Services
 - 6.1.3 Software
 - 6.2 Latin America Biosimulation Market (2017-2032) by Application
 - 6.2.1 Market Overview
 - 6.2.2 Drug Development
 - 6.2.3 Drug Discovery
 - 6.2.4 Other Application
 - 6.3 Latin America Biosimulation Market (2017-2032) by Delivery Type
 - 6.3.1 Market Overview
 - 6.3.2 Subscription Model
 - 6.3.3 Ownership Model

- 6.4 Latin America Biosimulation Market (2017-2032) by End User
 - 6.4.1 Market Overview
 - 6.4.2 Biotechnology & Pharmaceutical Companies
 - 6.4.3 Research Institutes
 - 6.4.4 Regulatory Authorities
 - 6.4.5 Contract Research Organizations
- 6.5 Latin America Biosimulation Market (2017-2032) by Country
 - 6.5.1 Market Overview
 - 6.5.2 Brazil
 - 6.5.3 Argentina
 - 6.5.4 Mexico
 - 6.5.5 Others
- 7 Brazil Biosimulation Market (2017-2032)
 - 7.1 Brazil Biosimulation Market (2017-2032) by Product Type
 - 7.1.1 Market Overview
 - 7.1.2 Services
 - 7.1.3 Software
 - 7.2 Brazil Biosimulation Market (2017-2032) by Application
 - 7.2.1 Market Overview
 - 7.2.2 Drug Development
 - 7.2.3 Drug Discovery
 - 7.2.4 Other Application
 - 7.3 Brazil Biosimulation Market (2017-2032) by Delivery Type
 - 7.3.1 Market Overview
 - 7.3.2 Subscription Model
 - 7.3.3 Ownership Model
 - 7.4 Brazil Biosimulation Market (2017-2032) by End User
 - 7.4.1 Market Overview
 - 7.4.2 Biotechnology & Pharmaceutical Companies
 - 7.4.3 Research Institutes
 - 7.4.4 Regulatory Authorities
 - 7.4.5 Contract Research Organizations
- 8 Argentina Biosimulation Market (2017-2032)
 - 8.1 Argentina Biosimulation Market (2017-2032) by Product Type
 - 8.1.1 Market Overview
 - 8.1.2 Services
 - 8.1.3 Software
 - 8.2 Argentina Biosimulation Market (2017-2032) by Application
 - 8.2.1 Market Overview
 - 8.2.2 Drug Development
 - 8.2.3 Drug Discovery
 - 8.2.4 Other Application
 - 8.3 Argentina Biosimulation Market (2017-2032) by Delivery Type
 - 8.3.1 Market Overview
 - 8.3.2 Subscription Model
 - 8.3.3 Ownership Model
 - 8.4 Argentina Biosimulation Market (2017-2032) by End User

- 8.4.1 Market Overview
- 8.4.2 Biotechnology & Pharmaceutical Companies
- 8.4.3 Research Institutes
- 8.4.4 Regulatory Authorities
- 8.4.5 Contract Research Organizations
- 9 Mexico Biosimulation Market (2017-2032)
 - 9.1 Mexico Biosimulation Market (2017-2032) by Product Type
 - 9.1.1 Market Overview
 - 9.1.2 Services
 - 9.1.3 Software
 - 9.2 Mexico Biosimulation Market (2017-2032) by Application
 - 9.2.1 Market Overview
 - 9.2.2 Drug Development
 - 9.2.3 Drug Discovery
 - 9.2.4 Other Application
 - 9.3 Mexico Biosimulation Market (2017-2032) by Delivery Type
 - 9.3.1 Market Overview
 - 9.3.2 Subscription Model
 - 9.3.3 Ownership Model
 - 9.4 Mexico Biosimulation Market (2017-2032) by End User
 - 9.4.1 Market Overview
 - 9.4.2 Biotechnology & Pharmaceutical Companies
 - 9.4.3 Research Institutes
 - 9.4.4 Regulatory Authorities
 - 9.4.5 Contract Research Organizations
- 10 Regulatory Framework
- 11 Funding and Investment Analysis
 - 11.1 Analysis by Funding Instances
 - 11.2 Analysis by Type of Funding
 - 11.3 Analysis by Funding Amount
 - 11.4 Analysis by Leading Players
 - 11.5 Analysis by Leading Investors
 - 11.6 Analysis by Geography
- 12 Partnership and Collaborations Analysis
 - 12.1 Analysis by Partnership Instances
 - 12.2 Analysis by Type of Partnership
 - 12.3 Analysis by Leading Players
 - 12.4 Analysis by Geography
- 13 Supplier Landscape
 - 13.1 Market Share by Top 5 Companies
 - 13.2 In Silico Biosciences
 - 13.2.1 Financial Analysis
 - 13.2.2 Product Portfolio
 - 13.2.3 Demographic Reach and Achievements
 - 13.2.4 Mergers and Acquisitions
 - 13.2.5 Certifications
 - 13.3 Biosimulation Solutions LLC

- 13.3.1 Financial Analysis
- 13.3.2 Product Portfolio
- 13.3.3 Demographic Reach and Achievements
- 13.3.4 Mergers and Acquisitions
- 13.3.5 Certifications
- 13.4 Solvias
 - 13.4.1 Financial Analysis
 - 13.4.2 Product Portfolio
 - 13.4.3 Demographic Reach and Achievements
 - 13.4.4 Mergers and Acquisitions
 - 13.4.5 Certifications
- 13.5 QuantumBio
 - 13.5.1 Financial Analysis
 - 13.5.2 Product Portfolio
 - 13.5.3 Demographic Reach and Achievements
 - 13.5.4 Mergers and Acquisitions
 - 13.5.5 Certifications
- 13.6 Biosimulation Technology
 - 13.6.1 Financial Analysis
 - 13.6.2 Product Portfolio
 - 13.6.3 Demographic Reach and Achievements
 - 13.6.4 Mergers and Acquisitions
 - 13.6.5 Certifications
- 13.7 Biocellion
 - 13.7.1 Financial Analysis
 - 13.7.2 Product Portfolio
 - 13.7.3 Demographic Reach and Achievements
 - 13.7.4 Mergers and Acquisitions
 - 13.7.5 Certifications
- 13.8 Certara
 - 13.8.1 Financial Analysis
 - 13.8.2 Product Portfolio
 - 13.8.3 Demographic Reach and Achievements
 - 13.8.4 Mergers and Acquisitions
 - 13.8.5 Certifications
- 13.9 Simulations Plus
 - 13.9.1 Financial Analysis
 - 13.9.2 Product Portfolio
 - 13.9.3 Demographic Reach and Achievements
 - 13.9.4 Mergers and Acquisitions
 - 13.9.5 Certifications
- 13.10 Rhenovia Pharma
 - 13.10.1 Financial Analysis
 - 13.10.2 Product Portfolio
 - 13.10.3 Demographic
 - 13.10.4 Mergers and Acquisitions
 - 13.10.5 Certifications

- 13.11 Heuristik
 - 13.11.1 Financial Analysis
 - 13.11.2 Product Portfolio
 - 13.11.3 Demographic Reach and Achievements
 - 13.11.4 Mergers and Acquisitions
 - 13.11.5 Certifications
- 14 Latin America Biosimulation Market Distribution Model (Additional Insight)
 - 14.1 Overview
 - 14.2 Potential Distributors
 - 14.3 Key Parameters for Distribution Partner Assessment
- 15 Key Opinion Leaders (KOL) Insights (Additional Insight)
- 16 Company Competitiveness Analysis (Additional Insight)
 - 16.1 Very Small Companies
 - 16.2 Small Companies
 - 16.3 Mid-Sized Companies
 - 16.4 Large Companies
 - 16.5 Very Large Companies
- 17 Payment Methods (Additional Insight)
 - 17.1 Government Funded
 - 17.2 Private Insurance
 - 17.3 Out-of-Pocket

* The coverage of the Market Landscape section depends on the data availability and may cover a minimum of 80% of the total market. The EMR team strives to make this section as comprehensive as possible.

^{*}Additional insights provided are customisable as per client requirements.



☐ - Print this form

To place an Order with Scotts International:

 $\hfill \Box$ - Complete the relevant blank fields and sign

Latin America Biosimulation Market Report and Forecast 2024-2032

Market Report | 2024-06-26 | 140 pages | EMR Inc.

Select license	License				Price
	Single User License			\$3999.00	
	Five User License			\$5299.00	
	Corporate License			\$6299.00	
				VAT Total	
		anies, individuals and EU based comp	anies who are	unubic to provide u	valia 20 vac
		Phone*	ariies wilo are	unable to provide a	valia 25 vac
Email*		Phone*	anies wild are	unable to provide a	Valid 25 val
Email* First Name*			anies who are	unable to provide a	
Email* First Name* ob title*		Phone* [Last Name* [unable to provide a	
Email* First Name* ob title* Company Name*		Phone* [Last Name* [BU Vat / Tax ID / NIP		unable to provide a	
Email* First Name* ob title* Company Name*		Phone* [Last Name* [
Email* First Name* ob title* Company Name* Address* Zip Code*		Phone* [Last Name* [BU Vat / Tax ID / NIP			
Email* First Name* ob title* Company Name* Address*		Phone* Last Name* EU Vat / Tax ID / NIP City* Country*			

Scotts International. EU Vat number: PL 6772247784